1. Home
  2. CDTX vs VACH Comparison

CDTX vs VACH Comparison

Compare CDTX & VACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDTX
  • VACH
  • Stock Information
  • Founded
  • CDTX 2012
  • VACH 2023
  • Country
  • CDTX United States
  • VACH United States
  • Employees
  • CDTX N/A
  • VACH N/A
  • Industry
  • CDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • VACH
  • Sector
  • CDTX Health Care
  • VACH
  • Exchange
  • CDTX Nasdaq
  • VACH NYSE
  • Market Cap
  • CDTX 980.1M
  • VACH 329.2M
  • IPO Year
  • CDTX 2015
  • VACH 2024
  • Fundamental
  • Price
  • CDTX $61.05
  • VACH $10.40
  • Analyst Decision
  • CDTX Strong Buy
  • VACH
  • Analyst Count
  • CDTX 11
  • VACH 0
  • Target Price
  • CDTX $52.11
  • VACH N/A
  • AVG Volume (30 Days)
  • CDTX 1.6M
  • VACH 31.4K
  • Earning Date
  • CDTX 08-12-2025
  • VACH 01-01-0001
  • Dividend Yield
  • CDTX N/A
  • VACH N/A
  • EPS Growth
  • CDTX N/A
  • VACH N/A
  • EPS
  • CDTX N/A
  • VACH 0.30
  • Revenue
  • CDTX $302,000.00
  • VACH N/A
  • Revenue This Year
  • CDTX N/A
  • VACH N/A
  • Revenue Next Year
  • CDTX N/A
  • VACH N/A
  • P/E Ratio
  • CDTX N/A
  • VACH $35.21
  • Revenue Growth
  • CDTX N/A
  • VACH N/A
  • 52 Week Low
  • CDTX $10.14
  • VACH $9.95
  • 52 Week High
  • CDTX $61.19
  • VACH $11.20
  • Technical
  • Relative Strength Index (RSI)
  • CDTX 75.12
  • VACH N/A
  • Support Level
  • CDTX $50.25
  • VACH N/A
  • Resistance Level
  • CDTX $55.75
  • VACH N/A
  • Average True Range (ATR)
  • CDTX 3.96
  • VACH 0.00
  • MACD
  • CDTX -0.04
  • VACH 0.00
  • Stochastic Oscillator
  • CDTX 95.28
  • VACH 0.00

About CDTX Cidara Therapeutics Inc.

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

About VACH VOYAGER ACQUISITION CORP.

Voyager Acquisition Corp is a blank check company.

Share on Social Networks: